# Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)

> **NCT04626518** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 370 (estimated)

## Conditions studied

- Carcinoma, Renal Cell

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **BIOLOGICAL:** MK-4830
- **DRUG:** Belzutifan
- **DRUG:** Lenvatinib
- **BIOLOGICAL:** Pembrolizumab/Quavonlimab
- **BIOLOGICAL:** Favezelimab/Pembrolizumab

## Key facts

- **NCT ID:** NCT04626518
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-12-17
- **Primary completion:** 2026-07-17
- **Final completion:** 2026-07-17
- **Target enrollment:** 370 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04626518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04626518, "Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04626518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*